bliss anti-stress formula Dietary Supplement, 60 Tablets; Manufactured For and
Recalling firm: Market America Inc
Potentially undeclared Yohimbe 83 and complaints of adverse reactions: upset stomach, jittery, sweaty, lightheaded or dizzy.
Historical recall record. This is not a new recall announcement. “Completed” describes the FDA recall process; it does not certify that an individual package is safe.
Check your package
Compare the exact product and package details with the label you have.
848570004703FDA code information
Lot #: 51130, Expiration Date: 07/2019 Manufacturer's Code PK-MA13173 Manufacturer's Item #Z02320
Match the product, package size, and code together. A missing match does not guarantee safety.
Full FDA record and distribution details
Original product description
bliss anti-stress formula Dietary Supplement, 60 Tablets; Manufactured For and distributed by: Market America, Inc., 1302 Pleasant Ridge Road, Greensboro, NC 27409; UPC 8 48570 00470 3
Extracted codes and context
| Type | Code / value | Context |
|---|---|---|
| UPC | 848570004703 | d by: Market America, Inc., 1302 Pleasant Ridge Road, Greensboro, NC 27409; UPC 8 48570 00470 3 |
Original FDA recall reason
Potentially undeclared Yohimbe 83 and complaints of adverse reactions: upset stomach, jittery, sweaty, lightheaded or dizzy.
Recall details
- Recall number
- F-0681-2020
- Event ID
- 84537
- FDA status
- Completed
- Initiated
- Oct 19, 2017
- Reported
- Feb 19, 2020
- Classified
- Feb 10, 2020
- Quantity
- 1,496/60 tablet bottles
- Location
- Greensboro, NC, United States
- Initiation type
- Voluntary: Firm initiated
- Notification
Where it was distributed
Product was shipped to the following states: AK, AL, AZ, CA, CO, CT, DE, FL, GA, HI, IA, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, MT, NC, ND, NH, NJ, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, VI, VT, WA, WI & WV. Product was also shipped to Australia, Canada & Hong Kong.
Data updated September 16, 2026. View official FDA data ↗
Follow official FDA and manufacturer guidance.